for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Biocon Ltd

BION.BO

Latest Trade

291.50INR

Change

1.05(+0.36%)

Volume

127,647

Today's Range

288.45

 - 

294.50

52 Week Range

211.30

 - 

341.43

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Latest Developments

Biocon Ltd Says True North To Invest 5.36 Bln Rupees In Biocon Biologics

Jan 6 (Reuters) - Biocon Ltd <BION.NS>::BIOCON LTD - TRUE NORTH TO INVEST 5.36 BILLION RUPEES IN BIOCON BIOLOGICS FOR 2.44% STAKE.BIOCON LTD - DEAL VALUES BIOCON BIOLOGICS AT $3 BILLION.BIOCON LTD - POST COMPLETION OF THIS TRANSACTION, BIOCON WILL HOLD 96.07% STAKE IN BIOCON BIOLOGICS.

Biocon, Equillium Expand Exclusive Licensing Deal For Itolizumab To Include Australia And New Zealand

Dec 12 (Reuters) - Biocon Ltd <BION.NS>::BIOCON & EQUILLIUM EXPAND EXCLUSIVE LICENSING AGREEMENT FOR ITOLIZUMAB TO INCLUDE AUSTRALIA AND NEW ZEALAND.

FDA Approves First Generics Of Gilenya

Dec 5 (Reuters) - U.S. Food and Drug Administration::FDA APPROVES FIRST GENERICS OF GILENYA.U.S. FDA - APPROVED 3 APPLICATIONS FOR FIRST GENERICS OF GILENYA CAPSULES FOR TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS IN ADULT PATIENTS.U.S. FDA - GRANTED APPROVALS OF GENERIC GILENYA (FINGOLIMOD) APPLICATIONS TO HEC PHARM CO LTD, BIOCON LTD AND SUN PHARMACEUTICAL INDUSTRIES LTD.

Biocon Say Siddharth Mittal Takes Over As CEO, Joint MD

Dec 3 (Reuters) - Biocon Ltd <BION.NS>::SIDDHARTH MITTAL TAKES OVER AS CEO AND JOINT MANAGING DIRECTOR OF BIOCON LIMITED.MITTAL TAKES OVER FROM ARUN CHANDAVARKAR WHO RETIRED AS CEO & JOINT MD OF CO ON NOV 30, 2019.

Biocon And Mylan Launch Trastuzumab Biosimilar, Ogivri In The U.S.

Dec 2 (Reuters) - Biocon Ltd <BION.NS>::BIOCON AND MYLAN LAUNCH TRASTUZUMAB BIOSIMILAR, OGIVRI (TRASTUZUMAB-DKST), IN U.S..

Biocon's Biologics Drug Products Facility In Bengaluru Gets EIR From U.S. FDA

Nov 5 (Reuters) - Biocon Ltd <BION.NS>::BIOCON'S BIOLOGICS DRUG PRODUCTS FACILITY IN BENGALURU RECEIVES EIR FROM U.S. FDA.

Biocon Ltd Appoints Siddharth Mittal As CEO

Oct 23 (Reuters) - Biocon Ltd <BION.NS>::SAYS COMPLETION OF TENURE OF ARUN SURESH CHANDAVARKAR AS CHIEF EXECUTIVE OFFICER AND JOINT MANAGING DIRECTOR.APPOINTMENT OF SIDDHARTH MITTAL AS CHIEF EXECUTIVE OFFICER AND JOINT MANAGING DIRECTOR.

India's Biocon Sept Quarter Consol Profit Falls

Oct 23 (Reuters) - Biocon Ltd <BION.NS>::SEPT QUARTER CONSOL PROFIT 2.16 BILLION RUPEES VERSUS PROFIT OF 3.55 BILLION RUPEES LAST YEAR.CONSENSUS FORECAST FOR SEPT QUARTER CONSOL PROFIT WAS 2.26 BILLION RUPEES.SEPT QUARTER CONSOL REVENUE FROM OPERATIONS 15.72 BILLION RUPEES VERSUS 13.21 BILLION RUPEES LAST YEAR.

Biocon And Mylan Launch First Insulin In Australia

Oct 3 (Reuters) - Biocon Ltd <BION.NS>::BIOCON AND MYLAN LAUNCH FIRST INSULIN GLARGINE BIOSIMILAR, SEMGLEE, IN AUSTRALIA.

India's Biocon Buys R&D Assets For Biologics Facility

Sept 24 (Reuters) - Biocon Ltd <BION.NS>::SAYS BIOCON BIOLOGICS EXPANDS ITS RESEARCH AND DEVELOPMENT FOOTPRINT THROUGH ACQUSITION..SAYS BOUGHT RESEARCH AND DEVELOPMENT CAPITAL ASSETS FOR A 60,000 SQ FT BIOLOGICS RESEARCH PLANT AT CHENNAI.DOES NOT DISCLOSE FINANCIAL DETAILS OF DEAL.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up